Posted by Michael Wonder on 23 Jul 2024
Johnson & Johnson seeks US FDA approval of Spravato (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
22 July 2024 - Phase 4 Spravato monotherapy data shows rapid improvement in depressive symptoms at ~24 hours, sustained through at least 4 weeks.
Johnson & Johnson announced today the submission of a supplemental new drug application to the US FDA seeking approval of Spravato (esketamine) nasal spray as a monotherapy for adults living with treatment-resistant depression.
